Registry update — unassessed
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle.
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTN=16Minor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 10, 2025 · Discovered: Sep 19, 2026 · Assessed: — · Historical research backfill
What it does not prove
- Study findings are not reported, so no conclusions about rapamycin's effects on aged muscle can be drawn from this material
- The small planned sample size (16 participants) limits generalizability regardless of results
- An abstract and aims statement do not constitute evidence of efficacy or safety
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 16
- Duration
- —
- Population
- Healthy male volunteers over 50 years old
- Primary outcome
- Effects of Rapamune on aged human muscle mass and function
- Effect size
- —
- Significance
- Not reported
- Journal
- University of Nottingham
- Published
- Apr 10, 2025
Sources
Primary source
- University of Nottingham ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The investigators aim to recruit 16 healthy male volunteers over 50 years old to investigate how the drug Rapamune (which blocks the mTOR pathway) affects aged human muscle both on its own and when combined with resistance exercise training.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.